Mitochondrial Composition for Energy and Oxidative Stress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial diseases, particularly those affecting the respiratory chain, are inadequate, with no validated therapies available, leading to limited options for managing symptoms and addressing the underlying energy production deficits and oxidative stress.
Innovation Solution
A composition comprising glucose, N-acetylcysteine, nicotinic acid, and optionally probucol, administered alone or in combination, is used to treat mitochondrial diseases, along with methods for screening therapeutic agents using genetically altered C. elegans, zebrafish, and human cells to identify modulators of mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vitamins and supplements are administered on an empiric basis, then there is an assumption of benefit to altered cellular metabolism, but the compounds are unregulated, unstandardized, untested, and not optimized for safety, potency, or effectiveness
Solution Approach 1:
The patent establishes specific concentration ranges for each compound in the composition (e.g., glucose 5-20 mM, N-acetylcysteine 1-10 mM, nicotinic acid 1-10 mM, probucol 0.1-5 μM) to optimize therapeutic effect. These standardized parameters transform unregulated empiric supplementation into a controlled, reproducible treatment protocol with defined potency and safety margins.
Solution Approach 2:
The patent creates a multi-functional composition that simultaneously addresses multiple pathological aspects of mitochondrial disease: energy production deficits (glucose), oxidative stress (N-acetylcysteine), mitochondrial signaling (nicotinic acid), and lipid metabolism/protein aggregation (probucol). This universal approach replaces multiple separate empiric supplements with a single standardized regimen.
2Adaptability or versatility
If multiple separate vitamins and supplements are used to address various mitochondrial dysfunction aspects, then coverage of different pathological mechanisms increases, but the complexity of the treatment regimen increases and optimization of each compound is not achieved
Solution Approach 1:
The patent merges four separate therapeutic agents into a single standardized composition with defined concentrations and administration protocols. This combination approach maintains the versatility of addressing multiple pathological mechanisms (energy production, oxidative stress, signaling, lipid metabolism) while simplifying the treatment regimen into one unified protocol rather than multiple separate supplements.
Solution Approach 2:
The treatment protocol functions as a composite therapeutic material, combining compounds with complementary mechanisms of action in specific ratios and concentrations. Each component targets a different aspect of mitochondrial pathology, and their synergistic interaction creates a more effective treatment than individual compounds alone, while the standardized formulation reduces regimen complexity.
3Ease of operation
If empirical supplementation is used without standardized protocols, then treatment can be initiated without complex screening, but the safety, potency, and effectiveness cannot be determined or optimized
Solution Approach 1:
The patent performs preliminary actions by establishing a fully optimized and standardized composition formulation before clinical application. Extensive preclinical screening and optimization were conducted to determine the exact concentrations and combinations of compounds that maximize therapeutic effect. This preliminary work enables straightforward clinical implementation without requiring complex real-time optimization, balancing ease of operation with proven effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described composition and methods demonstrate potential in alleviating symptoms and improving mitochondrial function in various mitochondrial diseases by enhancing energy production and reducing oxidative stress, as evidenced by improved cellular parameters and extended lifespan in animal models.
Implementation Method 1
reducing oxidative stress, as evidenced by improved cellular parameters
Implementation Method 2
enhancing energy production, as evidenced by improved cellular parameters
Data Source
AI summary
Compositions and methods for treatment of mitochondrial respiratory chain dysfunction and other mitochondrial disorders are provided. Also disclosed are a number of screening assays having utility for the identification of agents which modulate the phenotype associated with mitochondrial respiratory chain dysfunction.